ArticleFrontiers in pharmacology2026
Cost-effectiveness analysis of pyrotinib combined with trastuzumab and docetaxel as first-line treatment for HER2-positive metastatic breast cancer in China.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study assessed the cost-effectiveness of pyrotinib combined with trastuzumab and docetaxel as a first-line treatment for HER2-positive metastatic breast cancer from the perspective of the Chinese healthcare system. Methods: A partitioned survival model was constructed to evaluate the cost-effectiveness of this regimen in patients with HER2-positive metastatic breast cancer. The primary outcomes were total costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER). The treatment strategy was considered cost-effective when the ICER fell below a predefined willingness-to-pay (WTP) threshold. One-way and probabilistic sensitivity analyses were conducted to address parameter uncertainties. Additional scenario analyses were performed to explore how different assumptions influenced the ICER. Results: In the base-case analysis, the pyrotinib group incurred total costs of $136,400.69 compared with $83,887.55 in the placebo group. The corresponding effectiveness was 5.20 QALYs Conclusion: From the Chinese healthcare perspective, pyrotinib combined with trastuzumab and docetaxel may not be cost-effective for HER2-positive metastatic breast cancer under current prices and the WTP threshold. A price reduction would be required to achieve cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.